发明名称 |
ENGINEERING AND DELIVERY OF THERAPEUTIC COMPOSITIONS OF FRESHLY ISOLATED CELLS |
摘要 |
The present invention relates to the transient modification of cells. In particular embodiments, the cells are immune systems, such as PBMC, PBL, T (CD3+ and/or CD8+) and Natural Killer (NK) cells. The modified cells provide a population of cells that express a genetically engineered chimeric receptor which can be administered to a patient therapeutically. The present invention further relates to methods that deliver mRNA coding for the chimeric receptor to unstimulated resting PBMC, PBL, T (CD3+ and/or CD8+) and NK cells and which delivers the mRNA efficiently to the transfected cells and promotes significant target cell killing. |
申请公布号 |
EP2279253(A2) |
申请公布日期 |
2011.02.02 |
申请号 |
EP20090731422 |
申请日期 |
2009.04.09 |
申请人 |
MAXCYTE, INC. |
发明人 |
LI, LINHONG;PESHWA, MADHUSUDAN, V. |
分类号 |
A61K35/12;A61K35/17;A61K39/00;A61K39/395;A61K48/00;A61P35/02;C12N5/078;C12N5/0783;C12N13/00;C12N15/85 |
主分类号 |
A61K35/12 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|